Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sergey Shcherbinin

Showing results (41-50 of 74) with videos related to

Pageof 8
Sort By:
JAMA Neurology|September 12, 2022
Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes: The TRAILBLAZER-ALZ Randomized Clinical TrialSergey Shcherbinin, Cynthia D Evans, Ming Lu, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 23, 2025
Alzheimer's Imaging ConsortiumChris Conklin, Stefan Radonjic, David Scott, et al.
Annals of Neurology|October 14, 2023
Combined Connectomics, MAPT Gene Expression, and Amyloid Deposition to Explain Regional Tau Deposition in Alzheimer DiseaseLukai Zheng, Anna Rubinski, Jannis Denecke, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|May 22, 2018
Topographic staging of tau positron emission tomography imagesAdam J Schwarz, Sergey Shcherbinin, Lawrence J Slieker, et al.
Alzheimer'S & Dementia (New York, N. Y.)|August 21, 2023
Tau as a diagnostic instrument in clinical trials to predict amyloid in Alzheimer's diseaseSergey Shcherbinin, Amanda Morris, Ixavier A Higgins, et al.
Alzheimer'S Research & Therapy|November 8, 2022
Combining tau-PET and fMRI meta-analyses for patient-centered prediction of cognitive decline in Alzheimer's diseaseDavina Biel, Ying Luan, Matthias Brendel, et al.
The New England Journal of Medicine|March 15, 2021
Donanemab in Early Alzheimer's DiseaseMark A Mintun, Albert C Lo, Cynthia Duggan Evans, et al.
The Journal of Prevention of Alzheimer'S Disease|July 6, 2025
The effect of modified donanemab titration on amyloid-related imaging abnormalities with edema/effusions and amyloid reduction: 18-month results from TRAILBLAZER-ALZ 6Hong Wang, Emel Serap Monkul Nery, Paul Ardayfio, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 19, 2017
Pseudoreference Regions for Glial Imaging with <sup>11</sup>C-PBR28: Investigation in 2 Clinical CohortsDaniel S Albrecht, Marc D Normandin, Sergey Shcherbinin, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|June 11, 2026
Donanemab treatment effect by baseline tau burden and disease severity: Observations from the TRAILBLAZER-ALZ 2 trialLars L Raket, Ming Lu, Cynthia D Evans, et al.
Pageof 8

Showing results (41-50 of 74) with videos related to

Sort By:
Pageof 8
JAMA Neurology|September 12, 2022
Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes: The TRAILBLAZER-ALZ Randomized Clinical TrialSergey Shcherbinin, Cynthia D Evans, Ming Lu, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 23, 2025
Alzheimer's Imaging ConsortiumChris Conklin, Stefan Radonjic, David Scott, et al.
Annals of Neurology|October 14, 2023
Combined Connectomics, MAPT Gene Expression, and Amyloid Deposition to Explain Regional Tau Deposition in Alzheimer DiseaseLukai Zheng, Anna Rubinski, Jannis Denecke, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|May 22, 2018
Topographic staging of tau positron emission tomography imagesAdam J Schwarz, Sergey Shcherbinin, Lawrence J Slieker, et al.
Alzheimer'S & Dementia (New York, N. Y.)|August 21, 2023
Tau as a diagnostic instrument in clinical trials to predict amyloid in Alzheimer's diseaseSergey Shcherbinin, Amanda Morris, Ixavier A Higgins, et al.
Alzheimer'S Research & Therapy|November 8, 2022
Combining tau-PET and fMRI meta-analyses for patient-centered prediction of cognitive decline in Alzheimer's diseaseDavina Biel, Ying Luan, Matthias Brendel, et al.
The New England Journal of Medicine|March 15, 2021
Donanemab in Early Alzheimer's DiseaseMark A Mintun, Albert C Lo, Cynthia Duggan Evans, et al.
The Journal of Prevention of Alzheimer'S Disease|July 6, 2025
The effect of modified donanemab titration on amyloid-related imaging abnormalities with edema/effusions and amyloid reduction: 18-month results from TRAILBLAZER-ALZ 6Hong Wang, Emel Serap Monkul Nery, Paul Ardayfio, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 19, 2017
Pseudoreference Regions for Glial Imaging with <sup>11</sup>C-PBR28: Investigation in 2 Clinical CohortsDaniel S Albrecht, Marc D Normandin, Sergey Shcherbinin, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|June 11, 2026
Donanemab treatment effect by baseline tau burden and disease severity: Observations from the TRAILBLAZER-ALZ 2 trialLars L Raket, Ming Lu, Cynthia D Evans, et al.
Pageof 8